宫颈胃型腺癌发病机制及靶向免疫治疗研究进展
A Review of Progress in Pathogenesis and Immunotherapy Targeted Therapy of Gastric-Type Adenocarcinoma of the Uterine Cervix
DOI: 10.12677/acm.2025.15113160, PDF,   
作者: 陈慈香：赣南医科大学第一临床医学院，江西 赣州；卢增红, 王钇力*：赣南医科大学第一附属医院肿瘤内科，江西 赣州；江西省中西医协同旗舰建设科室，江西 赣州；江西省临床重点肿瘤专科建设单位，江西 赣州；江西省恶性肿瘤临床医学研究中心，江西 赣州
关键词: 宫颈胃型腺癌；Peutz-Jeghers综合征；分子生物学；免疫检查点；靶向治疗；Gastric-Type Endocervical Adenocarcinomas； Peutz-Jeghers Syndrome； Molecular Biology； Immune Checkpoint； Targeted Therapy
摘要: 临床上，宫颈胃型腺癌(Gastric-Type Endocervical Adenocarcinoma, GEAs)首诊症状多不典型，主要为阴道流液或腹部不适，内检时肉眼多为桶状宫颈表现。作为HPV非相关型宫颈腺癌(HPV Non-Associated Cervical Adenocarcinomas, NHPVAs)，GEAs病变隐匿，早期诊断率低，呈高度侵袭性，且易发生远处转移，复发率高，宫颈脱落细胞学及人乳头瘤病毒(Human Papilloma Virus, HPV)检测并不能满足GEAs的早期筛查。因此，本文将从疾病谱系变化及分子生物学层面阐述GEAs的发病机制，并对GEAs靶向治疗和免疫治疗的潜在靶点及药物研发进展进行系统综述，以期为临床诊治提供思路。
Abstract: Clinically, the initial symptoms of gastric-type endocervical adenocarcinoma (GEAs) are often atypical, mainly including vaginal discharge or abdominal discomfort. During internal examination, the lesion is usually manifested as a barrel-shaped cervix. As a type of HPV non-associated cervical adenocarcinoma (NHPVAs), GEAs have a concealed nature, a low rate of early diagnosis, high invasiveness, and a high risk of distant metastasis and recurrence. Cervical cytology and human papilloma virus (HPV) testing cannot meet the requirements for early screening of GEAs. Therefore, this article will elaborate on the pathogenesis of GEAs from the perspectives of disease spectrum changes and molecular biology, and conduct a systematic review of potential targets and drug development progress for targeted and immunotherapy of GEAs, with the aim of providing ideas for clinical diagnosis and treatment.
文章引用：陈慈香, 卢增红, 王钇力. 宫颈胃型腺癌发病机制及靶向免疫治疗研究进展[J]. 临床医学进展, 2025, 15(11): 775-784. https://doi.org/10.12677/acm.2025.15113160

参考文献

[1] Siegel, R.L., Miller, K.D., Wagle, N.S. and Jemal, A. (2023) Cancer Statistics, 2023. CA: A Cancer Journal for Clinicians, 73, 17-48. [Google Scholar] [CrossRef] [PubMed]
[2] Gadducci, A., Guerrieri, M.E. and Cosio, S. (2019) Adenocarcinoma of the Uterine Cervix: Pathologic Features, Treatment Options, Clinical Outcome and Prognostic Variables. Critical Reviews in Oncology/Hematology, 135, 103-114. [Google Scholar] [CrossRef] [PubMed]
[3] Stolnicu, S., Hoang, L. and Soslow, R.A. (2019) Recent Advances in Invasive Adenocarcinoma of the Cervix. Virchows Archiv, 475, 537-549. [Google Scholar] [CrossRef] [PubMed]
[4] Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Terinte, C., Pesci, A., et al. (2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix. American Journal of Surgical Pathology, 42, 214-226. [Google Scholar] [CrossRef] [PubMed]
[5] Kojima, A., Mikami, Y., Sudo, T., Yamaguchi, S., Kusanagi, Y., Ito, M., et al. (2007) Gastric Morphology and Immunophenotype Predict Poor Outcome in Mucinous Adenocarcinoma of the Uterine Cervix. American Journal of Surgical Pathology, 31, 664-672. [Google Scholar] [CrossRef] [PubMed]
[6] Lu, Z. and Chen, J. (2014) Introduction of WHO Classification of Tumours of Female Reproductive Organs, Fourth Edition. Chinese Journal of Pathology, 43, 649-650.
[7] Talia, K.L. and McCluggage, W.G. (2018) The Developing Spectrum of Gastric-Type Cervical Glandular Lesions. Pathology, 50, 122-133. [Google Scholar] [CrossRef] [PubMed]
[8] Ohta, Y., Suzuki, T., Hamatani, S., Shiokawa, A., Kushima, M. and Ota, H. (2008) Lobular Endocervical Glandular Hyperplasia Might Become a Precursor of Adenocarcinoma with Pyloric Gland Features. Pathology—Research and Practice, 204, 683-687. [Google Scholar] [CrossRef] [PubMed]
[9] Talia, K.L., Stewart, C.J.R., Howitt, B.E., Nucci, M.R. and McCluggage, W.G. (2017) HPV-Negative Gastric Type Adenocarcinoma in Situ of the Cervix: A Spectrum of Rare Lesions Exhibiting Gastric and Intestinal Differentiation. American Journal of Surgical Pathology, 41, 1023-1033. [Google Scholar] [CrossRef] [PubMed]
[10] Okuyama, R., Hashimoto, H., Miura, T., Sugita, M., Arai, M., Tsunoda, H., et al. (2017) Two Cases of Adenocarcinoma in Situ Arising in Lobular Endocervical Glandular Hyperplasia Indicating Localization of Mucin on the Cluster Surface as an Early Cytological Finding of Malignant Transformation. Diagnostic Cytopathology, 45, 842-847. [Google Scholar] [CrossRef] [PubMed]
[11] Gordhandas, S.B., Kahn, R., Sassine, D., Aviki, E.M., Baltich Nelson, B., Catchings, A., et al. (2022) Gastric-Type Adenocarcinoma of the Cervix in Patients with Peutz-Jeghers Syndrome: A Systematic Review of the Literature with Proposed Screening Guidelines. International Journal of Gynecological Cancer, 32, 79-88. [Google Scholar] [CrossRef] [PubMed]
[12] Ida, K., Miyamoto, T., Takatsu, A., Ando, H., Asaka, R., Takeuchi, H., et al. (2019) Whole‑exome Sequencing of Lobular Endocervical Glandular Hyperplasia. Oncology Letters, 18, 2592-2597. [Google Scholar] [CrossRef] [PubMed]
[13] 姜安绮, 康玉, 徐丛剑. Peutz-Jeghers综合征相关子宫颈胃型腺癌研究进展[J]. 中国实用妇科与产科杂志, 2023, 39(11): 1144-1148.
[14] Banno, K., Kisu, I., Yanokura, M., Masuda, K., Ueki, A., Kobayashi, Y., et al. (2013) Hereditary Gynecological Tumors Associated with Peutz-Jeghers Syndrome (Review). Oncology Letters, 6, 1184-1188. [Google Scholar] [CrossRef] [PubMed]
[15] 张国楠, 向阳, 王登凤, 等. 子宫颈胃型腺癌临床诊治中国专家共识(2021年版) [J]. 中国实用妇科与产科杂志, 2021, 37(11): 1131-1136.
[16] Yu, Z., Liu, L., Jiang, F., Ji, Y., Wang, X. and Liu, L. (2022) A Novel Missense Mutation of the STK11 Gene in a Chinese Family with Peutz-Jeghers Syndrome. BMC Gastroenterology, 22, Article No. 536. [Google Scholar] [CrossRef] [PubMed]
[17] Daniell, J., Plazzer, J., Perera, A. and Macrae, F. (2018) An Exploration of Genotype-Phenotype Link between Peutz-Jeghers Syndrome and STK11: A Review. Familial Cancer, 17, 421-427. [Google Scholar] [CrossRef] [PubMed]
[18] 张同真. Peutz-Jeghers综合征STK11基因突变筛查及与肠套叠和恶性肿瘤发生的相关性研究[D]: [硕士学位论文]. 张家口: 河北北方学院, 2021.
[19] Selenica, P., Alemar, B., Matrai, C., Talia, K.L., Veras, E., Hussein, Y., et al. (2021) Massively Parallel Sequencing Analysis of 68 Gastric-Type Cervical Adenocarcinomas Reveals Mutations in Cell Cycle-Related Genes and Potentially Targetable Mutations. Modern Pathology, 34, 1213-1225. [Google Scholar] [CrossRef] [PubMed]
[20] Park, E., Kim, S.W., Kim, S., Kim, H., Lee, J., Kim, Y.T., et al. (2021) Genetic Characteristics of Gastric-Type Mucinous Carcinoma of the Uterine Cervix. Modern Pathology, 34, 637-646. [Google Scholar] [CrossRef] [PubMed]
[21] Friedman, C.F., Ravichandran, V., Miller, K., Vanderbilt, C., Zhou, Q., Iasonos, A., et al. (2023) Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets. Clinical Cancer Research, 29, 4660-4668. [Google Scholar] [CrossRef] [PubMed]
[22] Lu, S., Shi, J., Zhang, X., Kong, F., Liu, L., Dong, X., et al. (2021) Comprehensive Genomic Profiling and Prognostic Analysis of Cervical Gastric-Type Mucinous Adenocarcinoma. Virchows Archiv, 479, 893-903. [Google Scholar] [CrossRef] [PubMed]
[23] Hodgson, A., Howitt, B.E., Park, K.J., Lindeman, N., Nucci, M.R. and Parra-Herran, C. (2019) Genomic Characterization of HPV-Related and Gastric-Type Endocervical Adenocarcinoma: Correlation with Subtype and Clinical Behavior. International Journal of Gynecological Pathology, 39, 578-586. [Google Scholar] [CrossRef] [PubMed]
[24] Garg, S., Nagaria, T.S., Clarke, B., Freedman, O., Khan, Z., Schwock, J., et al. (2019) Molecular Characterization of Gastric-Type Endocervical Adenocarcinoma Using Next-Generation Sequencing. Modern Pathology, 32, 1823-1833. [Google Scholar] [CrossRef] [PubMed]
[25] Moat, M., O’Donnell, R.L., McCluggage, W.G., Ralte, A. and Edmondson, R.J. (2014) Gastric-Type Adenocarcinoma of the Cervix in a Patient with Lynch Syndrome: A Case Report. Gynecologic Oncology Reports, 10, 41-43. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, M., Yuan, B., Zhou, Z. and Han, W. (2021) Clinicopathological Characteristics and Prognostic Factors of Cervical Adenocarcinoma. Scientific Reports, 11, Article No. 7506. [Google Scholar] [CrossRef] [PubMed]
[27] Lyu, B.J., Shi, H.Y., Shao, Y., et al. (2021) Endocervical Adenocarcinomas Classified by International Endocervical Adenocarcinoma Criteria and Classification: A Clinicopathological and Prognostic Analysis of 286 Cases. Chinese Journal of Pathology, 50, 1014-1019.
[28] 张国楠, 向阳, 王登凤, 等. 子宫颈胃型腺癌临床诊治中国专家共识(2023年版) [J]. 中国实用妇科与产科杂志, 2023, 39(6): 617-625.
[29] Takeuchi, S. (2016) Biology and Treatment of Cervical Adenocarcinoma. Chinese Journal of Cancer Research, 28, 254-262. [Google Scholar] [CrossRef] [PubMed]
[30] Kojima, A., Shimada, M., Mikami, Y., et al. (2018) Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. International Journal of Gynecological Cancer, 28, 99-106.
[31] Itkin, B., Garcia, A., Straminsky, S., Adelchanow, E.D., Pereyra, M., Haab, G.A., et al. (2021) Prevalence of HER2 Overexpression and Amplification in Cervical Cancer: A Systematic Review and Meta-Analysis. PLOS ONE, 16, e0257976. [Google Scholar] [CrossRef] [PubMed]
[32] Wang, S., Zhou, X., Niu, S., Chen, L., Zhang, H., Chen, H., et al. (2023) Assessment of HER2 in Gastric-Type Endocervical Adenocarcinoma and Its Prognostic Significance. Modern Pathology, 36, Article 100148. [Google Scholar] [CrossRef] [PubMed]
[33] Shi, H., Shao, Y., Lu, W. and Lu, B. (2021) An Analysis of HER2 Amplification in Cervical Adenocarcinoma: Correlation with Clinical Outcomes and the International Endocervical Adenocarcinoma Criteria and Classification. The Journal of Pathology: Clinical Research, 7, 86-95. [Google Scholar] [CrossRef] [PubMed]
[34] Ehmann, S., Sassine, D., Straubhar, A.M., Praiss, A.M., Aghajanian, C., Alektiar, K.M., et al. (2022) Gastric-Type Adenocarcinoma of the Cervix: Clinical Outcomes and Genomic Drivers. Gynecologic Oncology, 167, 458-466. [Google Scholar] [CrossRef] [PubMed]
[35] Oaknin, A., Friedman, C.F., Roman, L.D., D’Souza, A., Brana, I., Bidard, F., et al. (2020) Neratinib in Patients with HER2-Mutant, Metastatic Cervical Cancer: Findings from the Phase 2 SUMMIT Basket Trial. Gynecologic Oncology, 159, 150-156. [Google Scholar] [CrossRef] [PubMed]
[36] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the Destiny-Pantumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[37] Meng, H., Liu, J., Qiu, J., Nie, S., Jiang, Y., Wan, Y., et al. (2020) Identification of Key Genes in Association with Progression and Prognosis in Cervical Squamous Cell Carcinoma. DNA and Cell Biology, 39, 848-863. [Google Scholar] [CrossRef] [PubMed]
[38] Xie, G., Wang, Z., Chen, Y., Zhang, S., Feng, L., Meng, F., et al. (2017) Dual Blocking of PI3K and mTOR Signaling by NVP-BEZ235 Inhibits Proliferation in Cervical Carcinoma Cells and Enhances Therapeutic Response. Cancer Letters, 388, 12-20. [Google Scholar] [CrossRef] [PubMed]
[39] Jiang, W., Ouyang, X., Li, C., Long, Y., Chen, W., Ji, Z., et al. (2023) Targeting PI3Kα Increases the Efficacy of Anti-PD-1 Antibody in Cervical Cancer. Immunology, 170, 419-438. [Google Scholar] [CrossRef] [PubMed]
[40] Chung, H.C., Ros, W., Delord, J., Perets, R., Italiano, A., Shapira-Frommer, R., et al. (2019) Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. Journal of Clinical Oncology, 37, 1470-1478. [Google Scholar] [CrossRef] [PubMed]
[41] Wang, J., Lou, H., Cai, H., Huang, X., Li, G., Wang, L., et al. (2022) A Study of AK104 (an Anti-PD1 and Anti-CTLA4 Bispecific Antibody) Combined with Standard Therapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (R/M CC). Journal of Clinical Oncology, 40, 106. [Google Scholar] [CrossRef] 
[42] Gao, X., Xu, N., Li, Z., Shen, L., Ji, K., Zheng, Z., et al. (2023) Safety and Antitumour Activity of Cadonilimab, an Anti-PD-1/CTLA-4 Bispecific Antibody, for Patients with Advanced Solid Tumours (COMPASSION-03): A Multicentre, Open-Label, Phase 1b/2 Trial. The Lancet Oncology, 24, 1134-1146. [Google Scholar] [CrossRef] [PubMed]
[43] Bosse, T., Lax, S., Abu-Rustum, N. and Matias-Guiu, X. (2021) The Role of Predictive Biomarkers in Endocervical Adenocarcinoma: Recommendations from the International Society of Gynecological Pathologists. International Journal of Gynecological Pathology, 40, S102-S110. [Google Scholar] [CrossRef] [PubMed]
[44] 钟林, 周琦, 王海霞, 等. HPV感染与特殊类型宫颈腺癌预后相关性分析[J]. 重庆医科大学学报, 2021, 46(6): 700-703.
[45] Song, F., Jia, M., Yu, S., Cao, L., Sun, P. and Gao, H. (2021) PD-L1 Expression and Immune Stromal Features in HPV-Independent Cervical Adenocarcinoma. Histopathology, 79, 861-871. [Google Scholar] [CrossRef] [PubMed]
[46] Chen, L., Lucas, E., Zhang, X., Liu, Q., Zhuang, Y., Lin, W., et al. (2022) Programmed Death-Ligand 1 Expression in Human Papillomavirus-Independent Cervical Adenocarcinoma and Its Prognostic Significance. Histopathology, 80, 338-347. [Google Scholar] [CrossRef] [PubMed]
[47] Solinas, C., De Silva, P., Bron, D., Willard-Gallo, K. and Sangiolo, D. (2019) Significance of TIM3 Expression in Cancer: From Biology to the Clinic. Seminars in Oncology, 46, 372-379. [Google Scholar] [CrossRef] [PubMed]
[48] Sun, Y., Zhou, X., Lucas, E., Chen, L., Zhang, H., Chen, H., et al. (2023) Expression of B7-H3 and TIM-3 in Gastric-Type Endocervical Adenocarcinoma: Prevalence, Association with PD-l1 Expression, and Prognostic Significance. The Journal of Pathology: Clinical Research, 10, e345. [Google Scholar] [CrossRef] [PubMed]
[49] Hollebecque, A., Chung, H.C., de Miguel, M.J., Italiano, A., Machiels, J., Lin, C., et al. (2021) Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient Tumors. Clinical Cancer Research, 27, 6393-6404. [Google Scholar] [CrossRef] [PubMed]
[50] Qi, Y., Chen, L., Liu, Q., Kong, X., Fang, Y. and Wang, J. (2020) Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy. Frontiers in Immunology, 11, Article 563258. [Google Scholar] [CrossRef] [PubMed]
[51] Ge, Y., Zhang, Y., Zhao, K. and Zhu, H. (2022) Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer. Drug Design, Development and Therapy, 16, 3055-3070. [Google Scholar] [CrossRef] [PubMed]
[52] Luke, J.J., Patel, M.R., Blumenschein, G.R., Hamilton, E., Chmielowski, B., Ulahannan, S.V., et al. (2023) The PD-1-and LAG-3-Targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: A Phase 1 Trial. Nature Medicine, 29, 2814-2824. [Google Scholar] [CrossRef] [PubMed]

为你推荐